Heart Rhythm Management Center, Cardiovascular Center, Free University of Brussels (UZ Brussel) VUB, Brussels, Belgium.
Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):113-23. doi: 10.1016/j.bpg.2012.01.013.
Cardiovascular disease, which includes coronary heart disease, cerebrovascular disease and peripheral artery disease, is the leading cause of death in developed countries. Evidence from basic research, clinical investigations, observational epidemiologic studies and randomized clinical trials has provided strong support for the benefits of aspirin in decreasing the risk of cardiovascular events in a wide range of pathologies in secondary prevention. Data in primary prevention have far more uncertainties. An overview for the evidence supporting the efficacy of aspirin in primary and secondary prevention of cardiovascular disease is discussed, including the relative and absolute benefit and the risks of side effects. Finally, future developments in the field directed towards individualized treatment strategies and novel antiplatelet agents are examined.
心血管疾病包括冠心病、脑血管病和外周动脉疾病，是发达国家的主要死亡原因。基础研究、临床研究、观察性流行病学研究和随机临床试验的证据为阿司匹林在降低多种二级预防病理下心血管事件风险方面的益处提供了有力支持。一级预防的数据则存在更多的不确定性。本文讨论了支持阿司匹林在心血管疾病一级和二级预防中的疗效的证据概述，包括相对和绝对益处以及副作用风险。最后，还探讨了该领域针对个体化治疗策略和新型抗血小板药物的未来发展。
